ArticleTargeted oncology2023

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.

Maureen Caligiuri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.